SHARP, Study of Heart and Renal Protection   Sponsored by     Martin Landray, BM, University of Oxford, UK Colin B, Baignet, BM, University of Oxford, UK   Funded by     Merck Schering Plough U.S. National Coordinator Bertram L. Kasiske, MD, Department of Medicine, Hennepin County Medical Center Berman Center Co-Investigator Richard Grimm, MD, PhD   Eligibility     Participants may be men or women aged ≥40 years, with a history of chronic kidney disease. Participants must not have a definite history of myocardial infarction or coronary revascularisation procedure, a functioning renal transplant, or a living donor-related transplant planned. Participants’ nephrologist and primary care physician both must provide consent. The nephrologist must not believe that there is a definite indication for, or contraindication to, an HMG-CoA reductase inhibitor (“statin”) or ezetimibe. Other, more detailed, enrollment criteria are provided at individual clinic sites.   Participant Involvement     Participants take either a cholesterol lowering medication or placebo. The medication is provided by SHARP. Participants attend a screening visit, randomization visit, and 11 follow-up visits over five years. Blood work is drawn at each visit.   How to apply     The Berman Center is the U.S. Regional Coordinating Center for the SHARP study and is also a SHARP clinical site, enrolling participants locally. Please contact the Berman Center Site Coordinator, Cathy Heuer, RN, BSN, 612-341-7920.